|
Deferred Research And Development Arrangement (Details) (USD $)
|
3 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2014
|
Dec. 31, 2013
|
Sep. 30, 2014
Rexgene [Member]
|
Sep. 30, 2013
Rexgene [Member]
|
Sep. 30, 2014
Rexgene [Member]
|
Sep. 30, 2013
Rexgene [Member]
|
Dec. 31, 2003
Rexgene [Member]
|
Dec. 31, 2013
Rexgene [Member]
|
Sep. 30, 2014
Teva Pharmaceutical Industries, Ltd. [Member]
|
Dec. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Nov. 27, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||||||||
| Research and development arrangement, one-time fee | $ 1,500,000 | ||||||||||
| Reduction of research and development expenses | 18,750 | 18,750 | 56,250 | 56,250 | 158,630 | ||||||
| research and development period | 20 years | ||||||||||
| Deferred Research and Development Arrangement | 618,750 | 833,630 | 618,750 | 618,750 | 675,000 | 158,630 | |||||
| Royalties paid, percentage of net sales | 3.00% | ||||||||||
| Restricted Cash and Cash Equivalents, Noncurrent | $ 37,500 | $ 196,130 | $ 926,000 | ||||||||